{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T20:09:04Z","timestamp":1794427744557,"version":"4.9.1"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,1,20]],"date-time":"2024-01-20T00:00:00Z","timestamp":1705708800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,1,20]],"date-time":"2024-01-20T00:00:00Z","timestamp":1705708800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100012166","name":"National Key R&D Program of China","doi-asserted-by":"crossref","award":["2022YFE0200800"],"award-info":[{"award-number":["2022YFE0200800"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Research Fund for Tumors of Urinary System treatment in China","award":["020"],"award-info":[{"award-number":["020"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Exp Clin Cancer Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Non-muscle-invasive bladder cancer (NMIBC) is treated with transurethral resection of bladder tumor (TURBT) followed by intravesical instillation of chemotherapy or Bacillus Calmette\u2013Gu\u00e9rin therapy. However, these treatments have a high recurrence rate and side effects, emphasizing the need for alternative instillations. Previously, we revealed that expanded allogeneic human natural killer (NK) cells from peripheral blood are a promising cellular therapy for prostate cancer. However, whether NK cells exhibit a similar killing effect in bladder cancer (BCa) remains unknown.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Expansion, activation, and cryopreservation of allogeneic human NK cells obtained from peripheral blood were performed as we previously described. In vitro cytotoxicity was evaluated using the cell counting kit-8. The levels of perforin, granzyme B, interferon-\u03b3, tumor necrosis factor-\u03b1, and chemokines (C-C-motif ligand [CCL]1, CCL2, CCL20, CCL3L1, and CCL4; C-X-C-motif ligand [CXCL]1, CXCL16, CXCL2, CXCL3, and CXCL8; and X-motif ligand 1 and 2) were determined using enzyme-linked immunosorbent assay. The expression of CD107a, major histocompatibility complex class I (MHC-I), MHC-I polypeptide-related sequences A and B (MICA\/B), cytomegalovirus UL16-binding protein-2\/5\/6 (ULBP-2\/5\/6), B7-H6, CD56, CD69, CD25, killer cell Ig-like receptors (KIR)2DL1, KIRD3DL1, NKG2D, NKp30, NKp46, and CD16 of NK cells or BCa and normal urothelial cells were detected using flow cytometry. Cytotoxicity was evaluated using lactate dehydrogenase assay in patient-derived organoid models. BCa growth was monitored in vivo using calipers in male NOD-scid IL2rg\u2212\/\u2212 mice subcutaneously injected with 5637 and NK cells. Differential gene expressions were investigated using RNA sequence analysis. The chemotaxis of T cells was evaluated using transwell migration assays.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>We revealed that the NK cells possess higher cytotoxicity against BCa lines with more production of cytokines than normal urothelial cells counterparts in vitro, demonstrated by upregulation of degranulation marker CD107a and increased interferon-\u03b3 secretion, by MICA\/B\/NKG2D and B7H6\/NKp30-mediated activation. Furthermore, NK cells demonstrated antitumor effects against BCa in patient-derived organoids and BCa xenograft mouse models. NK cells secreted chemokines, including CCL1\/2\/20, to induce T-cell chemotaxis when encountering BCa cells.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The expanded NK cells exhibit potent cytotoxicity against BCa cells, with few toxic side effects on normal urothelial cells. In addition, NK cells recruit T cells by secreting a panel of chemokines, which supports the translational application of NK cell intravesical instillation after TURBT from bench to bedside for NMIBC treatment.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13046-024-02955-7","type":"journal-article","created":{"date-parts":[[2024,1,20]],"date-time":"2024-01-20T02:02:46Z","timestamp":1705716166000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["High and selective cytotoxicity of ex vivo expanded allogeneic human natural killer cells from peripheral blood against bladder cancer: implications for natural killer cell instillation after transurethral resection of bladder tumor"],"prefix":"10.1186","volume":"43","author":[{"given":"Fangming","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianli","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianlin","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuai","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuzhe","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Song","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianxing","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nianzeng","family":"Xing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,1,20]]},"reference":[{"issue":"3","key":"2955_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, et al. Global Cancer statistics 2020: GLOBOCAN estimates of incidence and Mortality Worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209\u201349. https:\/\/doi.org\/10.3322\/caac.21660.","journal-title":"CA Cancer J Clin"},{"issue":"5","key":"2955_CR2","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1038\/s41571-023-00744-3","volume":"20","author":"LMC van Hoogstraten","year":"2023","unstructured":"van Hoogstraten LMC, Vrieling A, van der Heijden AG, Kogevinas M, Richters A, Kiemeney LA. Global trends in the epidemiology of bladder cancer: challenges for public health and clinical practice. Nat Rev Clin Oncol. 2023;20(5):287\u2013304. https:\/\/doi.org\/10.1038\/s41571-023-00744-3.","journal-title":"Nat Rev Clin Oncol"},{"issue":"1","key":"2955_CR3","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.eururo.2021.08.010","volume":"81","author":"M Babjuk","year":"2022","unstructured":"Babjuk M, Burger M, Capoun O, et al. European Association of Urology Guidelines on non-muscle-invasive bladder Cancer (Ta, T1, and carcinoma in situ). Eur Urol. 2022;81(1):75\u201394. https:\/\/doi.org\/10.1016\/j.eururo.2021.08.010.","journal-title":"Eur Urol"},{"key":"2955_CR4","unstructured":"American Urological Association. Diagnosis and treatment of non-muscle invasive bladder cancer: AUA\/SUO joint guideline. 2016. Available at: https:\/\/www.auanet.org\/guidelines\/bladder-cancer-non-muscle-invasive-guideline."},{"issue":"2","key":"2955_CR5","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.ajur.2015.04.016","volume":"2","author":"K Li","year":"2015","unstructured":"Li K, Lin T, Chinese Bladder Cancer Consortium. Current status of diagnosis and treatment of bladder cancer in China - analyses of Chinese bladder Cancer Consortium database. Asian J Urol. 2015;2(2):63\u20139. https:\/\/doi.org\/10.1016\/j.ajur.2015.04.016.","journal-title":"Asian J Urol"},{"issue":"12","key":"2955_CR6","doi-asserted-by":"publisher","first-page":"6278","DOI":"10.1172\/JCI139597","volume":"130","author":"X Chen","year":"2020","unstructured":"Chen X, Zhang J, Ruan W, et al. Urine DNA methylation assay enables early detection and recurrence monitoring for bladder cancer. J Clin Invest. 2020;130(12):6278\u201389. https:\/\/doi.org\/10.1172\/JCI139597.","journal-title":"J Clin Invest"},{"issue":"5","key":"2955_CR7","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1038\/s41585-022-00578-1","volume":"19","author":"JY Teoh","year":"2022","unstructured":"Teoh JY, Kamat AM, Black PC, Grivas P, Shariat SF, Babjuk M. Recurrence mechanisms of non-muscle-invasive bladder cancer -a clinical perspective. Nat Rev Urol. 2022;19(5):280\u201394. https:\/\/doi.org\/10.1038\/s41585-022-00578-1.","journal-title":"Nat Rev Urol"},{"issue":"6","key":"2955_CR8","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1308\/003588410X12664192076935","volume":"92","author":"RT Bryan","year":"2010","unstructured":"Bryan RT, Collins SI, Daykin MC, et al. Mechanisms of recurrence of Ta\/T1 bladder cancer. Ann R Coll Surg Engl. 2010;92(6):519\u201324. https:\/\/doi.org\/10.1308\/003588410X12664192076935.","journal-title":"Ann R Coll Surg Engl"},{"issue":"4","key":"2955_CR9","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1016\/j.euf.2018.07.023","volume":"4","author":"M Babjuk","year":"2018","unstructured":"Babjuk M, Burger M, Comp\u00e9rat EM, et al. Indication for a single postoperative instillation of Chemotherapy in non-muscle-invasive bladder Cancer: what factors should be considered? Eur Urol Focus. 2018;4(4):525\u20138. https:\/\/doi.org\/10.1016\/j.euf.2018.07.023.","journal-title":"Eur Urol Focus"},{"issue":"6","key":"2955_CR10","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1517\/14656566.2015.1024656","volume":"16","author":"SG Patel","year":"2015","unstructured":"Patel SG, Cohen A, Weiner AB, Steinberg GD. Intravesical therapy for bladder cancer. Expert Opin Pharmacother. 2015;16(6):889\u2013901. https:\/\/doi.org\/10.1517\/14656566.2015.1024656.","journal-title":"Expert Opin Pharmacother"},{"issue":"6","key":"2955_CR11","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1158\/0008-5472.CAN-21-2691","volume":"82","author":"Y Wang","year":"2022","unstructured":"Wang Y, Zhang Y, Li PC, et al. Development of Novel Aptamer-based targeted chemotherapy for bladder Cancer. Cancer Res. 2022;82(6):1128\u201339. https:\/\/doi.org\/10.1158\/0008-5472.CAN-21-2691.","journal-title":"Cancer Res"},{"issue":"5","key":"2955_CR12","doi-asserted-by":"publisher","first-page":"1964","DOI":"10.1016\/S0022-5347(05)64273-5","volume":"168","author":"RJ Sylvester","year":"2002","unstructured":"Sylvester RJ, van der MEIJDEN AP, Lamm DL. Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials. J Urol. 2002;168(5):1964\u201370. https:\/\/doi.org\/10.1016\/S0022-5347(05)64273-5.","journal-title":"J Urol"},{"issue":"2","key":"2955_CR13","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1111\/tri.12484","volume":"28","author":"T Roumegu\u00e8re","year":"2015","unstructured":"Roumegu\u00e8re T, Broeders N, Jayaswal A, et al. Bacillus Calmette-Guerin therapy in non-muscle-invasive bladder carcinoma after renal transplantation for end-stage aristolochic acid nephropathy. Transpl Int. 2015;28(2):199\u2013205. https:\/\/doi.org\/10.1111\/tri.12484.","journal-title":"Transpl Int"},{"issue":"5","key":"2955_CR14","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1038\/ni1582","volume":"9","author":"E Vivier","year":"2008","unstructured":"Vivier E, et al. Functions of natural killer cells. Nat Immunol. 2008;9(5):503\u201310.","journal-title":"Nat Immunol"},{"issue":"2","key":"2955_CR15","doi-asserted-by":"publisher","first-page":"205","DOI":"10.4161\/onci.1.2.18398","volume":"1","author":"M Salagianni","year":"2012","unstructured":"Salagianni M, Baxevanis CN, Papamichail M, Perez SA. New insights into the role of NK cells in cancer immunotherapy. Oncoimmunology. 2012;1(2):205\u20137. https:\/\/doi.org\/10.4161\/onci.1.2.18398.","journal-title":"Oncoimmunology"},{"issue":"22","key":"2955_CR16","doi-asserted-by":"publisher","first-page":"e163620","DOI":"10.1172\/JCI163620","volume":"132","author":"X Ren","year":"2022","unstructured":"Ren X, Peng M, Xing P, et al. Blockade of the immunosuppressive KIR2DL5\/PVR pathway elicits potent human NK cell-mediated antitumor immunity. J Clin Invest. 2022;132(22):e163620. https:\/\/doi.org\/10.1172\/JCI163620.","journal-title":"J Clin Invest"},{"key":"2955_CR17","doi-asserted-by":"publisher","first-page":"1869","DOI":"10.3389\/fimmu.2018.01869","volume":"9","author":"AM Abel","year":"2018","unstructured":"Abel AM, Yang C, Thakar MS, Malarkannan S. Natural killer cells: Development, Maturation, and clinical utilization. Front Immunol. 2018;9:1869. https:\/\/doi.org\/10.3389\/fimmu.2018.01869.","journal-title":"Front Immunol"},{"issue":"2","key":"2955_CR18","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1189\/jlb.0611308","volume":"91","author":"R Wang","year":"2012","unstructured":"Wang R, Jaw JJ, Stutzman NC, Zou Z, Sun PD. Natural killer cell-produced IFN-\u03b3 and TNF-\u03b1 induce target cell cytolysis through up-regulation of ICAM-1. J Leukoc Biol. 2012;91(2):299\u2013309. https:\/\/doi.org\/10.1189\/jlb.0611308.","journal-title":"J Leukoc Biol"},{"issue":"6013","key":"2955_CR19","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1126\/science.1198687","volume":"331","author":"E Vivier","year":"2011","unstructured":"Vivier E, Raulet DH, Moretta A, et al. Innate or adaptive immunity? The example of natural killer cells. Science. 2011;331(6013):44\u20139. https:\/\/doi.org\/10.1126\/science.1198687.","journal-title":"Science"},{"key":"2955_CR20","doi-asserted-by":"publisher","first-page":"216300","DOI":"10.1016\/j.canlet.2023.216300","volume":"568","author":"F Wang","year":"2023","unstructured":"Wang F, Liu S, Liu F, et al. TIGIT immune checkpoint blockade enhances immunity of human peripheral blood NK cells against castration-resistant prostate cancer [published online ahead of print, 2023 Jul 4]. Cancer Lett. 2023;568:216300. https:\/\/doi.org\/10.1016\/j.canlet.2023.216300.","journal-title":"Cancer Lett"},{"key":"2955_CR21","doi-asserted-by":"publisher","first-page":"1786395","DOI":"10.1155\/2022\/1786395","volume":"2022","author":"F Wang","year":"2022","unstructured":"Wang F, Dong X, Wang J, et al. Allogeneic expanded human peripheral NK cells control prostate Cancer growth in a preclinical mouse model of castration-resistant prostate Cancer. J Immunol Res. 2022;2022:1786395. https:\/\/doi.org\/10.1155\/2022\/1786395.","journal-title":"J Immunol Res"},{"issue":"6","key":"2955_CR22","doi-asserted-by":"publisher","first-page":"e901","DOI":"10.1002\/ctm2.901","volume":"12","author":"F Wang","year":"2022","unstructured":"Wang F, Wu L, Yin L, Shi H, Gu Y, Xing N. Combined treatment with anti-PSMA CAR NK-92 cell and anti-PD-L1 monoclonal antibody enhances the antitumour efficacy against castration-resistant prostate cancer. Clin Transl Med. 2022;12(6):e901. https:\/\/doi.org\/10.1002\/ctm2.901.","journal-title":"Clin Transl Med"},{"issue":"28","key":"2955_CR23","doi-asserted-by":"publisher","first-page":"e2203357","DOI":"10.1002\/advs.202203357","volume":"9","author":"Q Zhang","year":"2022","unstructured":"Zhang Q, Deng T, Zhang H, et al. Adipocyte-derived exosomal MTTP suppresses ferroptosis and promotes Chemoresistance in Colorectal Cancer. Adv Sci (Weinh). 2022;9(28):e2203357. https:\/\/doi.org\/10.1002\/advs.202203357.","journal-title":"Adv Sci (Weinh)"},{"issue":"6","key":"2955_CR24","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1016\/j.eururo.2020.09.006","volume":"78","author":"JY Teoh","year":"2020","unstructured":"Teoh JY, Huang J, Ko WY, et al. Global trends of bladder Cancer incidence and mortality, and their associations with Tobacco Use and Gross Domestic Product per Capita. Eur Urol. 2020;78(6):893\u2013906. https:\/\/doi.org\/10.1016\/j.eururo.2020.09.006.","journal-title":"Eur Urol"},{"issue":"1","key":"2955_CR25","first-page":"31","volume":"10","author":"E Pasin","year":"2008","unstructured":"Pasin E, Josephson DY, Mitra AP, Cote RJ, Stein JP. Superficial bladder cancer: an update on etiology, molecular development, classification, and natural history. Rev Urol. 2008;10(1):31\u201343.","journal-title":"Rev Urol"},{"issue":"5","key":"2955_CR26","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1038\/s41585-021-00441-9","volume":"18","author":"P Mariappan","year":"2021","unstructured":"Mariappan P. Attention to detail and a permissive set-up: crucial for an effective TURBT. Nat Rev Urol. 2021;18(5):253\u20134. https:\/\/doi.org\/10.1038\/s41585-021-00441-9.","journal-title":"Nat Rev Urol"},{"issue":"3","key":"2955_CR27","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1016\/j.eururo.2011.05.045","volume":"60","author":"S van den Bosch","year":"2011","unstructured":"van den Bosch S, Alfred Witjes J. Long-term cancer-specific survival in patients with high-risk, non-muscle-invasive bladder cancer and tumour progression: a systematic review. Eur Urol. 2011;60(3):493\u2013500. https:\/\/doi.org\/10.1016\/j.eururo.2011.05.045.","journal-title":"Eur Urol"},{"issue":"1","key":"2955_CR28","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/s40779-022-00406-y","volume":"9","author":"YH Jin","year":"2022","unstructured":"Jin YH, Zeng XT, Liu TZ, et al. Treatment and surveillance for non-muscle-invasive bladder cancer: a clinical practice guideline (2021 edition). Mil Med Res. 2022;9(1):44. https:\/\/doi.org\/10.1186\/s40779-022-00406-y.","journal-title":"Mil Med Res"},{"issue":"3","key":"2955_CR29","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1038\/s41573-019-0052-1","volume":"19","author":"N Shimasaki","year":"2020","unstructured":"Shimasaki N, Jain A, Campana D. NK cells for cancer immunotherapy. Nat Rev Drug Discov. 2020;19(3):200\u201318. https:\/\/doi.org\/10.1038\/s41573-019-0052-1.","journal-title":"Nat Rev Drug Discov"},{"issue":"9","key":"2955_CR30","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1016\/s0962-8924(01)02064-5","volume":"11","author":"V Baud","year":"2001","unstructured":"Baud V, Karin M. Signal transduction by tumor necrosis factor and its relatives. Trends Cell Biol. 2001;11(9):372\u20137. https:\/\/doi.org\/10.1016\/s0962-8924(01)02064-5.","journal-title":"Trends Cell Biol"},{"issue":"26","key":"2955_CR31","doi-asserted-by":"publisher","first-page":"14708","DOI":"10.1039\/c9ra02660f","volume":"9","author":"H Yang","year":"2019","unstructured":"Yang H, Wang M, Huang Y, Qiao Q, Zhao C, Zhao M. In vitro and in vivo evaluation of a novel mitomycin nanomicelle delivery system. RSC Adv. 2019;9(26):14708\u201317. https:\/\/doi.org\/10.1039\/c9ra02660f.","journal-title":"RSC Adv"},{"issue":"4","key":"2955_CR32","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1038\/nrurol.2014.52","volume":"11","author":"H Zargar","year":"2014","unstructured":"Zargar H, Aning J, Ischia J, So A, Black P. Optimizing intravesical mitomycin C therapy in non-muscle-invasive bladder cancer. Nat Rev Urol. 2014;11(4):220\u201330. https:\/\/doi.org\/10.1038\/nrurol.2014.52.","journal-title":"Nat Rev Urol"},{"key":"2955_CR33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.taap.2016.12.011","volume":"316","author":"SE Farr","year":"2017","unstructured":"Farr SE, Chess-Williams R, McDermott CM, Gemcitabine. Selective cytotoxicity, induction of inflammation and effects on urothelial function. Toxicol Appl Pharmacol. 2017;316:1\u20139. https:\/\/doi.org\/10.1016\/j.taap.2016.12.011.","journal-title":"Toxicol Appl Pharmacol"},{"issue":"16","key":"2955_CR34","doi-asserted-by":"publisher","first-page":"e202200342","DOI":"10.1002\/asia.202200342","volume":"17","author":"F Huo","year":"2022","unstructured":"Huo F, Zhang Y, Li Y, et al. Mannose-targeting Concanavalin A-Epirubicin Conjugate for targeted intravesical chemotherapy of bladder Cancer. Chem Asian J. 2022;17(16):e202200342. https:\/\/doi.org\/10.1002\/asia.202200342.","journal-title":"Chem Asian J"},{"issue":"1","key":"2955_CR35","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1186\/s12943-020-01238-x","volume":"19","author":"SY Wu","year":"2020","unstructured":"Wu SY, Fu T, Jiang YZ, Shao ZM. Natural killer cells in cancer biology and therapy. Mol Cancer. 2020;19(1):120. https:\/\/doi.org\/10.1186\/s12943-020-01238-x.","journal-title":"Mol Cancer"},{"key":"2955_CR36","first-page":"284","volume":"6","author":"EM Garcia-Cuesta","year":"2015","unstructured":"Garcia-Cuesta EM, Lopez-Cobo S, Alvarez-Maestro M, Esteso G, Romera-Cardenas G, Rey M, et al. NKG2D is a key receptor for recognition of bladder cancer cells by IL-2-activated NK cells and BCG promotes NK cell activation. Front Immunol. 2015;6:284.","journal-title":"Front Immunol"},{"issue":"1","key":"2955_CR37","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1186\/s12916-016-0715-2","volume":"14","author":"M Ferreira-Teixeira","year":"2016","unstructured":"Ferreira-Teixeira M, Paiva-Oliveira D, Parada B, et al. Natural killer cell-based adoptive immunotherapy eradicates and drives differentiation of chemoresistant bladder cancer stem-like cells. BMC Med. 2016;14(1):163. https:\/\/doi.org\/10.1186\/s12916-016-0715-2.","journal-title":"BMC Med"},{"issue":"2","key":"2955_CR38","doi-asserted-by":"publisher","first-page":"169","DOI":"10.3233\/BLC-180167","volume":"4","author":"TCM Zuiverloon","year":"2018","unstructured":"Zuiverloon TCM, de Jong FC, Costello JC, Theodorescu D. Systematic review: characteristics and preclinical uses of bladder Cancer cell lines. Bladder Cancer. 2018;4(2):169\u201383. https:\/\/doi.org\/10.3233\/BLC-180167. Published 2018 Apr 26.","journal-title":"Bladder Cancer"},{"issue":"3","key":"2955_CR39","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/j.eururo.2022.03.009","volume":"82","author":"IE Ertl","year":"2022","unstructured":"Ertl IE, Lemberger U, Ilijazi D, et al. Molecular and pharmacological bladder Cancer Therapy Screening: Discovery of Clofarabine as a highly active compound. Eur Urol. 2022;82(3):261\u201370. https:\/\/doi.org\/10.1016\/j.eururo.2022.03.009.","journal-title":"Eur Urol"},{"issue":"1","key":"2955_CR40","doi-asserted-by":"publisher","first-page":"2214","DOI":"10.1038\/s41467-023-37696-2","volume":"14","author":"M Minoli","year":"2023","unstructured":"Minoli M, Cantore T, Hanhart D, et al. Bladder cancer organoids as a functional system to model different disease stages and therapy response. Nat Commun. 2023;14(1):2214. https:\/\/doi.org\/10.1038\/s41467-023-37696-2. Published 2023 Apr 18.","journal-title":"Nat Commun"},{"issue":"568","key":"2955_CR41","doi-asserted-by":"publisher","first-page":"eaaz5618","DOI":"10.1126\/scitranslmed.aaz5618","volume":"12","author":"F Cichocki","year":"2020","unstructured":"Cichocki F, Bjordahl R, Gaidarova S, et al. iPSC-derived NK cells maintain high cytotoxicity and enhance in vivo tumor control in concert with T cells and anti-PD-1 therapy. Sci Transl Med. 2020;12(568):eaaz5618. https:\/\/doi.org\/10.1126\/scitranslmed.aaz5618.","journal-title":"Sci Transl Med"},{"issue":"3","key":"2955_CR42","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.4049\/jimmunol.1401903","volume":"194","author":"E Hartung","year":"2015","unstructured":"Hartung E, Becker M, Bachem A, et al. Induction of potent CD8 T cell cytotoxicity by specific targeting of antigen to cross-presenting dendritic cells in vivo via murine or human XCR1. J Immunol. 2015;194(3):1069\u201379. https:\/\/doi.org\/10.4049\/jimmunol.1401903.","journal-title":"J Immunol"},{"issue":"5","key":"2955_CR43","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1016\/j.immuni.2009.08.027","volume":"31","author":"BG Dorner","year":"2009","unstructured":"Dorner BG, Dorner MB, Zhou X, et al. Selective expression of the chemokine receptor XCR1 on cross-presenting dendritic cells determines cooperation with CD8\u2009+\u2009T cells. Immunity. 2009;31(5):823\u201333. https:\/\/doi.org\/10.1016\/j.immuni.2009.08.027.","journal-title":"Immunity"},{"issue":"2","key":"2955_CR44","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1189\/jlb.71.2.173","volume":"71","author":"MJ Robertson","year":"2002","unstructured":"Robertson MJ. Role of chemokines in the biology of natural killer cells. J Leukoc Biol. 2002;71(2):173\u201383.","journal-title":"J Leukoc Biol"},{"issue":"20","key":"2955_CR45","doi-asserted-by":"publisher","first-page":"7619","DOI":"10.3390\/ijms21207619","volume":"21","author":"J Korbecki","year":"2020","unstructured":"Korbecki J, Grochans S, Gutowska I, Barczak K, Baranowska-Bosiacka I. CC chemokines in a Tumor: a review of Pro-cancer and Anti-cancer properties of receptors CCR5, CCR6, CCR7, CCR8, CCR9, and CCR10 ligands. Int J Mol Sci. 2020;21(20):7619. https:\/\/doi.org\/10.3390\/ijms21207619.","journal-title":"Int J Mol Sci"},{"issue":"24","key":"2955_CR46","doi-asserted-by":"publisher","first-page":"eabi5781","DOI":"10.1126\/sciadv.abi5781","volume":"7","author":"BL Cadilha","year":"2021","unstructured":"Cadilha BL, Benmebarek MR, Dorman K, et al. Combined tumor-directed recruitment and protection from immune suppression enable CAR T cell efficacy in solid tumors. Sci Adv. 2021;7(24):eabi5781. https:\/\/doi.org\/10.1126\/sciadv.abi5781.","journal-title":"Sci Adv"},{"key":"2955_CR47","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/1479-5876-9-33","volume":"9","author":"K Berencsi","year":"2011","unstructured":"Berencsi K, Rani P, Zhang T, et al. In vitro migration of cytotoxic T lymphocyte derived from a colon carcinoma patient is dependent on CCL2 and CCR2. J Transl Med. 2011;9:33. https:\/\/doi.org\/10.1186\/1479-5876-9-33.","journal-title":"J Transl Med"},{"issue":"12","key":"2955_CR48","doi-asserted-by":"publisher","first-page":"6673","DOI":"10.4049\/jimmunol.1300434","volume":"190","author":"T Lan\u00e7a","year":"2013","unstructured":"Lan\u00e7a T, Costa MF, Gon\u00e7alves-Sousa N, et al. Protective role of the inflammatory CCR2\/CCL2 chemokine pathway through recruitment of type 1 cytotoxic \u03b3\u03b4 T lymphocytes to tumor beds. J Immunol. 2013;190(12):6673\u201380. https:\/\/doi.org\/10.4049\/jimmunol.1300434.","journal-title":"J Immunol"},{"issue":"29","key":"2955_CR49","doi-asserted-by":"publisher","first-page":"E5900","DOI":"10.1073\/pnas.1706559114","volume":"114","author":"V Chew","year":"2017","unstructured":"Chew V, Lai L, Pan L, et al. Delineation of an immunosuppressive gradient in hepatocellular carcinoma using high-dimensional proteomic and transcriptomic analyses. Proc Natl Acad Sci U S A. 2017;114(29):E5900\u20139. https:\/\/doi.org\/10.1073\/pnas.1706559114.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"17","key":"2955_CR50","first-page":"5505","volume":"63","author":"M Crittenden","year":"2003","unstructured":"Crittenden M, Gough M, Harrington K, Olivier K, Thompson J, Vile RG. Expression of inflammatory chemokines combined with local tumor destruction enhances tumor regression and long-term immunity. Cancer Res. 2003;63(17):5505\u201312.","journal-title":"Cancer Res"},{"issue":"18","key":"2955_CR51","doi-asserted-by":"publisher","first-page":"4557","DOI":"10.1158\/0008-5472","volume":"79","author":"DC Hinshaw","year":"2019","unstructured":"Hinshaw DC, Shevde LA. The Tumor Microenvironment innately modulates Cancer Progression. Cancer Res. 2019;79(18):4557\u201366. https:\/\/doi.org\/10.1158\/0008-5472.","journal-title":"Cancer Res"},{"issue":"5","key":"2955_CR52","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1002\/cac2.12284","volume":"42","author":"M Huang","year":"2022","unstructured":"Huang M, Dong W, Xie R, et al. HSF1 facilitates the multistep process of lymphatic metastasis in bladder cancer via a novel PRMT5-WDR5-dependent transcriptional program. Cancer Commun (Lond). 2022;42(5):447\u201370. https:\/\/doi.org\/10.1002\/cac2.12284.","journal-title":"Cancer Commun (Lond)"},{"issue":"11","key":"2955_CR53","doi-asserted-by":"publisher","first-page":"e2205613","DOI":"10.1002\/advs.202205613","volume":"10","author":"Q Zhang","year":"2023","unstructured":"Zhang Q, Liu S, Wang H, et al. ETV4 mediated Tumor-Associated Neutrophil Infiltration facilitates lymphangiogenesis and lymphatic metastasis of bladder Cancer. Adv Sci (Weinh). 2023;10(11):e2205613. https:\/\/doi.org\/10.1002\/advs.202205613.","journal-title":"Adv Sci (Weinh)"},{"issue":"3","key":"2955_CR54","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1084\/jem.20010938","volume":"195","author":"F Gerosa","year":"2002","unstructured":"Gerosa F, Baldani-Guerra B, Nisii C, Marchesini V, Carra G, Trinchieri G. Reciprocal activating interaction between natural killer cells and dendritic cells. J Exp Med. 2002;195(3):327\u201333. https:\/\/doi.org\/10.1084\/jem.20010938.","journal-title":"J Exp Med"},{"issue":"3","key":"2955_CR55","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.4049\/jimmunol.172.3.1333","volume":"172","author":"G Ferlazzo","year":"2004","unstructured":"Ferlazzo G, M\u00fcnz C. NK cell compartments and their activation by dendritic cells. J Immunol. 2004;172(3):1333\u20139. https:\/\/doi.org\/10.4049\/jimmunol.172.3.1333.","journal-title":"J Immunol"}],"container-title":["Journal of Experimental &amp; Clinical Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-024-02955-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13046-024-02955-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-024-02955-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,20]],"date-time":"2024-01-20T02:07:31Z","timestamp":1705716451000},"score":1,"resource":{"primary":{"URL":"https:\/\/jeccr.biomedcentral.com\/articles\/10.1186\/s13046-024-02955-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,20]]},"references-count":55,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["2955"],"URL":"https:\/\/doi.org\/10.1186\/s13046-024-02955-7","relation":{},"ISSN":["1756-9966"],"issn-type":[{"value":"1756-9966","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,20]]},"assertion":[{"value":"17 October 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 January 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 January 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The studies involving animals and human participants were reviewed and approved by the Ethical Committee of Beijing Tsinghua Changgung Hospital and National Cancer Center (Ethical approval number: NCC2021C-535).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"24"}}